EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma

Kevin Campbell iD, Andrew Posner, Nan Chen, Kerri Cavanaugh, Ketki Bhushan, Katherine A Janeway iD, David S Shulman iD, Suzanne George, Kelly Klega, Brian Crompton, Wendy B London iD, Steven G DuBois iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30681 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Kevin Campbell und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Sarcoma, Ewing, Bone Neoplasms, Osteosarcoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: T32.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Phase 1 study assessing the safety and toxicity of cabozantinib in combination with topotecan and cyclophosphamide for relapsed osteosarcoma and Ewing sarcoma.

Methods

Oral cabozantinib (25 mg/m 2 ) was administered daily for 21 (dose level 1) or 14 (dose level −1B) days. Topotecan (0.75 mg/m 2 ) and cyclophosphamide (250 mg/m 2 ) were administered intravenously (IV) on days 1–5. A modified 3+3 design based upon first cycle dose‐limiting toxicities (DLT) was used for dose escalation.

Results

Twelve patients with a median age of 15 (12.9–33.2) years were enrolled (seven with Ewing sarcoma; five with osteosarcoma); all were evaluable for toxicity. At dose level 1, three of six patients developed first cycle DLT: grade 3 epistaxis, grade 3 transaminitis, and prolonged grade 2 thrombocytopenia. Six patients were enrolled on dose level −1B (interrupted cabozantinib, given days 8–21), with one first cycle DLT (grade 3 pneumothorax) observed. Of the 10 response evaluable patients, one had partial response (Ewing sarcoma), seven had stable disease, and two had progressive disease.

Conclusions

The recommended phase 2 doses and schedules for this combination are topotecan 0.75 mg/m 2 IV days 1–5, cyclophosphamide 250 mg/m 2 IV days 1–5, and cabozantinib 25 mg/m 2 days 8–21. Non‐concomitant administration of cabozantinib with cytotoxic therapy in this population has acceptable toxicity, while allowing for potential disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsSarcoma, EwingBone NeoplasmsOsteosarcomaNeoplasm Recurrence, LocalHumansTopotecanMaleFemaleAdolescentAdultPyridinesChildCyclophosphamideAnilidesYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

cabozantinibcyclophosphamidephase 1relapsed Ewing sarcomarelapsed osteosarcomatopotecan

Substanzen

TopotecancabozantinibPyridinesCyclophosphamideAnilides

Autor:innen und Institutionen

  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Kevin Campbell, Katherine A Janeway, David S Shulman, Wendy B London, Steven G DuBois

Förderung

  • T32

Zitieren

APA

Campbell, K., Posner, A., Chen, N., Cavanaugh, K., Bhushan, K., Janeway, K. A., Shulman, D. S., George, S., Klega, K., Crompton, B., London, W. B., & DuBois, S. G. (2023). Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30681

Vancouver

Campbell K, Posner A, Chen N, Cavanaugh K, Bhushan K, Janeway KA, et al. Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30681

BibTeX
@article{Campbell2023,
  author = {Campbell, Kevin and Posner, Andrew and Chen, Nan and Cavanaugh, Kerri and Bhushan, Ketki and Janeway, Katherine A and Shulman, David S and George, Suzanne and Klega, Kelly and Crompton, Brian and London, Wendy B and DuBois, Steven G},
  title = {Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30681}
}
Kostenlos starten →